Editorial commentary: Weight loss for cardiovascular disease prevention - is semaglutide the answer?

Affiliations

¹ John Ochsner Heart and Vascular Institute, Ochsner Clinical School-the University of Queensland School of Medicine, 1514 Jefferson Highway, New Orleans, LA 70121-2483, USA. Electronic address: clavie@ochsner.org.
² Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.
³ UH Center for Cardiovascular Prevention and Center for Integrated, and Novel Approaches in Vascular-Metabolic Disease (CINEMA), Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland OH, USA.
⁴ Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA.

Editorial

Carl J Lavie et al. Trends Cardiovasc Med. 2023 Apr.

. 2023 Apr;33(3):167-169.

doi: 10.1016/j.tcm.2021.12.018. Epub 2022 Jan 5.

¹ John Ochsner Heart and Vascular Institute, Ochsner Clinical School-the University of Queensland School of Medicine, 1514 Jefferson Highway, New Orleans, LA 70121-2483, USA. Electronic address: clavie@ochsner.org.
² Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.
³ UH Center for Cardiovascular Prevention and Center for Integrated, and Novel Approaches in Vascular-Metabolic Disease (CINEMA), Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland OH, USA.
⁴ Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA.

No abstract available

Comment on

Semaglutide for the treatment of obesity.
Chao AM, Tronieri JS, Amaro A, Wadden TA. Chao AM, et al. Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21. Trends Cardiovasc Med. 2023. PMID: 34942372 Free PMC article. Review.